ON THE COVER
“I joined the Children’s Tumor Foundation NF Endurance team 12 years ago to raise money for NF research. One day, my son Alex decided he wanted to start running and help raise awareness. My youngest son, Robby, who has NF1, and my other son, Mateo (not pictured) all trained together. Robby (left) and Alex (right) ran the Big Sur International Marathon together to raise money for NF research. Even though Alex had the ability to finish the run at a faster time, he decided he was going to stay and run it side by side with his brother. But leave it to a little brotherly rivalry as they approached the finish, they decided to finish with a full out sprint to the finish line. My husband and I were cheering them on at the finish line and it brought a smile to my face to see them supporting each other.”

-as told by Leticia Learno, Robby and Alex’s mom, who also has NF1

What is NF?

Neurofibromatosis (NF) is a term for three distinct genetic disorders: NF1, NF2, and schwannomatosis. NF affects 1 in every 3,000 people. It causes tumors to grow on nerves throughout the body and can lead to blindness, deafness, bone abnormalities, learning disabilities, disabling pain, and cancer. NF affects people of every population equally, and there is not yet a cure.
The Children’s Tumor Foundation (CTF) began as the first grassroots organization solely dedicated to finding treatments for NF. Today, CTF is a highly recognized national nonprofit foundation, the leading force in the fight to end NF, and a model for other innovative research endeavors.

**Our mission**

Drive research, expand knowledge, and advance care for the NF community.

**Our vision**

End NF.
“The Children’s Tumor Foundation has made a promise to dismantle the barriers that stand in the way of drug discovery. The fulfillment of that promise is in sight.”

— Annette Bakker, PhD, President and Chief Scientific Officer
Dear friends,

COLLABORATION was the guiding principle for 2015 at the Children’s Tumor Foundation (CTF), both in spirit and in action. Clinicians, scientists, patients, family members, volunteers, donors, fundraisers, industry members, and advocates—we have a single vision: a cure for neurofibromatosis (NF).

Because of the success of the Synodos for NF2 consortia, and thanks to the philanthropic leadership of Jim Bob and Laurée Moffett, in late 2015 we launched Synodos for NF1. Because of the generosity of many of you, the Moffett’s extraordinary $2.5 million matching gift was met.

Not long ago, the Children’s Tumor Foundation made a promise to dismantle the barriers that stand in the way of drug discovery. And now the fulfillment of that promise is in sight; because of your careful investments through the years, we are getting closer and closer to finding effective treatments. This past year we saw a clinical trial for the MEK inhibitor selumetinib, the most promising compound to date, shrink inoperable plexiform neurofibromas. CTF was critical in funding preclinical testing of this compound, and hopes are high that it will become the first ever FDA-approved NF treatment.

These are just a few of the accomplishments this past year in the world of NF research. We are celebrating many other victories here at the Children’s Tumor Foundation: the success of our many community events, increased engagement in the patient and researcher communities, and a growing number of volunteers and donors.

Our inspirational 2015 CTF Ambassador Jeff Hanson won the NASCAR Foundation’s Betty Jane France Humanitarian Award. Through the collective efforts of Jeff, his family, and all of your votes, Jeff brought home the $100,000 prize for CTF and NF research.

Our vision at the Children’s Tumor Foundation is lofty, and as we grow, we rely even more on the outstanding generosity of you, our extended family of donors, fundraisers, patients, and volunteers. Every dollar you have given brings into clearer focus the day that we will see a world without NF. Your hope is our vision, an end to NF.

— Annette Bakker, PhD, President and Chief Scientific Officer
“It gives me energy and hope to know that you are willing to come together and collaborate. And I hope that you will see the face of the patient on your darkest days and it will motivate you to keep up the fight. Because we’re counting on you, we really, really are.”

— Renie Moss, Synodos for NF1 Patient Advocate, speaking to the Synodos for NF1 researchers in their first group meeting in Minneapolis, Minnesota.
From 2010 to 2015, the Children’s Tumor Foundation's primary objective has been to fill the clinical drug development pipeline. We strategically integrated our investments into this clinical pipeline, resulting in substantial accomplishments by the end of those five years:

- **Over 70% of all NF data** in the world has been funded or co-funded by CTF.
- CTF investments in the last five years ($26.6M) have already attracted **$38.4M in follow-up funding** from other sources.
- CTF’s NF Preclinical Consortium and NF Therapeutic Consortium (NFPC and NFTC) have generated **95 preclinical studies** which have led to **16 clinical trials**.
- One of those trials (MEK inhibitor) resulted in more than 50% of participants in a clinical trial seeing **a reduction of at least 20% in their inoperable plexiform neurofibromas**.
- CTF created the **NF Registry**, which attracted more than 6,600 patients by the end of 2015, and whose information was utilized 18 times to recruit patients to clinical trials.
- The CTF **Biobank** collected more than 200 tissue samples.
- CTF funding led to more than **62 publications** in top peer-reviewed scientific journals.
- CTF built an **innovative research model called Synodos**, which attracted a “dream team” of scientists who pledged to work together collaboratively.
- CTF launched an **NF data hub**, providing an open access data platform to all.

The accomplishments of the past enable us to turn our eyes toward new goals. Our strategy for the next five years is to double the speed of getting effective therapies to the clinic. We are advancing our Synodos consortia, increasing our NF data hub, and expanding the NF Registry. With your help, our hope for the future includes partnerships with pharmaceutical and biotech companies, and the discovery of NF biomarkers that measure biological indicators for NF.

We are planning for a future in which there are approved treatments available for use in care of patients with NF!
The Children’s Tumor Foundation stands firmly on the belief that solutions to NF will be born through collaboration. We strive to bring researchers, patients, and experts together in a unified vision: to collaborate, share data, and accelerate the drug discovery path to the clinic.

**Synodos for NF1**
Launched in 2015, Synodos for NF1 is made up of three separate consortia based on the original Synodos for NF2 model. These three consortia bring together 24 investigators from eight leading institutions and two companies. Two teams form the Preclinical Acceleration component, and focus on the development of a swine model that will inform and better develop clinical trials in humans. This model will closely resemble a human’s response to a potential treatment. These two teams share the goal of accelerating the path to a cure, but use different technologies and target different genetics to mimic NF1. The third Synodos for NF1 team works to develop treatments for Low Grade Glioma (LGG), the most common childhood brain tumor affecting children with NF1. This group plans to transform the understanding of the cellular and molecular underpinnings of these unique tumors.

**Synodos for NF2**
Synodos for NF2 was established in 2014 and brings together multidisciplinary investigators from a host of centers of excellence who collaborate and share their data in real time. The Synodos for NF2 steering committee reviewed results of this collaborative team’s ongoing experiments in early November 2015. Principal Investigators from eight institutions presented the findings of their work from the first year of this three-year, three-million-dollar collaboration. Analysis of the first year’s results show that promising new drug combinations, as potential treatments for NF2, are emerging from the data. These combinations will soon be tested in cells and in animal models.

**The Neurofibromatosis Therapeutic Consortium (NFTC)** brings together four labs to find novel targets for clinical trials. This three-year, $4 million collaboration is co-funded with NTAP (Neurofibromatosis Therapeutic Acceleration Program) and is an extension of the Neurofibromatosis Preclinical Consortium (NFPC), a five-year, $7 million program that concluded in 2013. The collaborative nature of both the NFPC and the NFTC promotes efficiency and has advanced preclinical discovery beyond what would have been achieved by labs working individually. These two consortia cooperated to perform and complete 95 preclinical trials across different models. These studies have identified 12 drug targets with promising efficacy, and 16 clinical trials have occurred based on the preclinical data gathered by NFPC and NFTC investigators.
**NF Conference**

Over 300 of the top NF researchers and clinicians from more than 15 countries around the world gathered in Monterey, California, from June 6th to 9th for the annual 2015 NF Conference. The four day event, which is the world’s largest gathering of scientists and clinicians dedicated to advancing research and care for those living with NF1, NF2, and schwannomatosis, boasted a packed agenda that was both provocative and stimulating. Participants returned home with valuable new knowledge and relationships as a sure solid foundation for future, fruitful collaborations.

There was an abundance of promising clinical findings presented at the 2015 NF Conference. Among them, Scott Plotkin, MD, PhD of Harvard Medical School and Massachusetts General Hospital, shared results of clinical trials studying the effects of bevacizumab on hearing loss for patients with NF2, which affected durable improvement in hearing for nearly 50% of involved patients.

**Progress: MEK inhibitor**

At the NF Conference, it was announced that for the first time in the history of the treatment of plexiform neurofibromas (PNs), over 50% of patients saw decreased volume in these inoperable tumors. In a presentation titled “The Promise of MEK: Therapeutics for NF1,” Brigitte Widemann, MD, of the National Cancer Institute, reported that response data in a phase I trial for children and young adults is showing meaningful decreases in tumor volume. Anecdotal improvement in function and reduction in PN-related pain and disfigurement was also observed.

This highly successful clinical study is the result of a major investment of the Children’s Tumor Foundation NF Preclinical Consortium, wherein Nancy Ratner, PhD and D. Wade Clapp, MD demonstrated that MEK inhibitors (MEKi) have a massive result on PN tumor volume in mice.

---

**“We came to the conclusion that the Children’s Tumor Foundation was the RIGHT place for us to invest in finding NF treatments and hopefully, one day soon, to find a cure!”**

— Laurée Moffett, upon accepting the Children’s Humanitarian Award at the Children’s Tumor Foundation 2015 New York Gala

---

“What is Synodos?”

“Synodos” is a groundbreaking research collaboration of the Children’s Tumor Foundation, and represents a significant financial commitment on the part of the Foundation. Modeled after the success of “Stand-Up to Cancer,” in each Synodos collaboration all stakeholders (doctors, scientists, patients) work together to speed the drug discovery process. All data is analyzed by our partners at Sage Bionetworks. This data is shared immediately among Synodos team members, and shortly thereafter, with the rest of the world. CTF scientists serve as project leaders and manage milestones, ensuring that each project keeps moving toward optimum success.

---

**“Synodos” is a groundbreaking research collaboration of the Children’s Tumor Foundation, and represents a significant financial commitment on the part of the Foundation. Modeled after the success of “Stand-Up to Cancer,” in each Synodos collaboration all stakeholders (doctors, scientists, patients) work together to speed the drug discovery process. All data is analyzed by our partners at Sage Bionetworks. This data is shared immediately among Synodos team members, and shortly thereafter, with the rest of the world. CTF scientists serve as project leaders and manage milestones, ensuring that each project keeps moving toward optimum success.**
The Children’s Tumor Foundation is pleased to have funded six Young Investigator Awards in 2015. The YIA is the Foundation’s oldest research award program and serves to advance understanding of the biology of NF1, NF2, and schwannomatosis. Of the six awardees, three are predoctoral students and three are postdoctoral fellows who are doing basic research on all forms of NF and its complications. These young scientists will be funded through this award for two years, which we hope will encourage them to pursue lifelong careers in the field of NF research, and further the basic understanding of NF biology.

Drug Discovery Initiative Award (DDI) The DDI award funds early stage research that allows researchers to quickly screen high-risk/high-potential compounds in both cell and animal models. CTF awarded eight Drug Discovery Initiative awards in 2015. Four of these awards will target novel therapies for NF1-related tumors, and four will target for NF2-related tumor therapies.

Clinical Research Award (CRA) The Clinical Research Award program supports early-stage NF research involving human subjects. These awards support studies of candidate therapeutics or other interventions for the treatment of NF1, NF2, or schwannomatosis; clinical-trial-enabling or ancillary studies; natural history studies; and investigations into clinical care in NF. In 2015, two CRAs were awarded, one for a Skype-based psychosocial intervention for people with NF2, and the other to fund a sub-study within an NF1-related optic pathway glioma multicenter research project.
Biobank/Body Donation Program
Originally set up to collect dermal neurofibroma surgical samples, the CTF Biobank was broadened to collect tumors, nerve, bone, and other NF1 tissues post-mortem. The tissue comes from people who previously requested that CTF arrange for them to donate their bodies to research after death. Late in 2015, the Foundation received approval to begin banking tissue from people with either NF2 or schwannomatosis. CTF’s procedure for body donation will ensure that NF1, NF2, and schwannomatosis tissue be made widely available, promising to speed treatment development.

Biomarkers
The Children’s Tumor Foundation and the National Biomarker Development Alliance announced a partnership to advance biomarker development in NF with potential for applications across other rare disease areas. The field of pediatric tumors suffers from a lack of biomarkers, and nowhere is this more evident than in children’s tumors associated with neurofibromatosis. The absence of standardized, measurable biological indicators (biomarkers) makes NF even more difficult to diagnose and treat, resulting in fear and frustration not only for patients, but also for the doctors and clinicians working to better their lives. In coming years, the Children’s Tumor Foundation hopes to solve the problem of the absence of approved, measurable biological indicators for NF.
Neurofibromatosis Clinic Network (NFCN)
The Children’s Tumor Foundation is eager to get specialized NF care to more patients around the country. In 2015, the NF Clinic Network grew to 50 clinics that serve 10,000 patients. Clinics are invited to join the NFCN based on many factors including expertise in NF care, access to specialists, number of patients seen, and commitment to educating colleagues and patients about the latest developments. NFCN clinics also demonstrate a willingness to foster relationships with local patient support groups.

NF Forum
The NF Forum originated out of a desire to bring NF patients, families, caregivers, and friends together in an inviting atmosphere of education and fellowship. The 2015 NF Forum proved no exception. Nearly 300 people gathered in Arizona to be inspired, to learn, and to unite as one large NF family. The Forum was preceded by CTF’s Volunteer & Leadership Summit, designed to train and nurture active Foundation volunteers to become even stronger advocates in the fight to end NF. It was a full schedule of talks by expert NF clinicians, and concluded with the Scottsdale NF Walk.

NF Registry
The NF Registry can be accessed at nfregistry.org and is designed to serve all patients and researchers in NF. It is a voluntary online registry that uses a secure system for collecting patient data via surveys. Based on participant answers, registrants can receive information about relevant clinical trials, view trends and averages to see how they are like and unlike other people with NF, and take an active role in finding new treatments. The NF Registry has already been shown to speed clinical trial recruitment. So far, 18 clinical trials have found participants through the NF Registry.

“What I walk away with after five days: a strong sense of family and togetherness, and sincere gratitude for those that have gone before me and paved the way in the field of NF to grow CTF to what it is today.”

— Nicole Steinert, NF Forum attendee
The Volunteer & Leadership Summit
The Volunteer & Leadership Summit took place in Scottsdale, Arizona on April 15th and 16th in advance of the NF Forum. The summit provided an opportunity for our active volunteers to learn how to become more effective fundraisers, grow their events, connect with other volunteers throughout the country, and learn more about the many programs the Foundation offers. Breakout sessions included information about Regional Development, Awareness Month, NF Walk, NF Endurance, Racing4Research, Cupid’s Undie Run, and more. Volunteers made new connections and became more knowledgeable about the Foundation and our efforts to end NF.

NF Camp
Over 70 youth attended the 19th annual NF Camp, which took place in two sessions in July. NF Camp is held annually at the beautiful Camp Kostopulos in Emigration Canyon, Utah. Campers enjoyed horseback riding, rope courses, whitewater rafting, and day trips to places like Boondock’s Food & Fun and Lagoon Adventure Park. New friendships were forged, old friendships invigorated, and lasting memories were made at NF Camp 2015.

“At first I volunteered because it was something I could do to help my son. But within weeks of becoming involved it became so much more than that. I began to meet other volunteers and CTF staff. I started realizing that I wanted to fight for them as well. Now I can’t stop until there is a cure for everyone. I believe CTF is the organization that is going to find it. The organization’s dedication and drive to find a cure is truly remarkable.”
— Shannon McNall, NF Mom and CTF volunteer

“My friends at home are great, but the bond that I have with the people that have NF, same as me, is unbreakable. They are my second family and they know what I am going through.”
— Tegan, Utah, NF Camper
The Children’s Tumor Foundation is committed to expanding knowledge of neurofibromatosis by providing the most up-to-date information about NF on our website, ctf.org, and in the Foundation’s publications. A vibrant presence on social media engages and strengthens the bonds of the NF community, and spreads our message (and vision) of ending NF to those without an immediate NF connection. This past year saw the Foundation grow its media outreach efforts with countless articles in newspapers across the country, and TV and radio stations broadcasting segments that featured stories of dedicated volunteers, NF walkers and endurance athletes, and most importantly, our NF Heroes.
May is NF Awareness Month, and in 2015 the Children’s Tumor Foundation launched a new theme, “I KNOW A FIGHTER,” to draw attention to the inspirational and remarkable stories of those living with NF, who are fighters in every sense of the word. Members of the NF community were instrumental in promoting NF awareness by working with local government on city or state proclamations, organizing fundraisers, and sharing their stories online. Local and national media took notice of NF awareness month with coverage of fundraising events, proclamations, and the Foundation’s “Shine a Light on NF” campaign, through which many landmarks across the United States and around the world lit up in blue and green during the month of May for NF awareness.

— Michele, mom to Adam, who lives with NF
“Jesse was two when he was diagnosed with NF1. He has been so involved with CTF that as a toddler, he used to think that their logo was his name – because he always saw his picture next to it as his family fundraised. Today, he is so aware of the CTF mission that he regularly asks if the scientists have found the cure yet. This is why we walk. We really want to tell him yes.” — Jill Markland, mom to Jesse, who lives with NF

Racing4Research
Our Racing4Research program uses professional auto racing to increase awareness of neurofibromatosis and raise funds through corporate sponsorship, personal donations, and individual fundraising. Special thanks to our amazing NF Hero families who join us, rain or shine, to cheer on the drivers and teams that support the Children’s Tumor Foundation. The 2015 race season saw the Foundation logo carried on 17 race cars, with more than 500 NF families visiting the track, wearing the blue CTF T-shirts, and enjoying incredible VIP access throughout the paddock.

NF Walk
The NF Walk program brings together families and friends for fun-filled, inspirational events. Frequent appearances of costumed characters, balloon animals, and face painting bring bubbling energy from start to finish. Each event is as unique as the location where it is held. In 2015, thanks to an outstanding group of volunteer organizers, NF Walk exceeded its $1 million fundraising mark for the Children’s Tumor Foundation!
Community Events
One-of-a-kind fundraising events including tea parties, comedy nights, fashion shows, and lemonade stands, are supported by our Regional Development team. These events, held throughout the year, connect our nationwide team of volunteers with their immediate communities while raising funds for NF research.

NF Endurance
No challenge is too much for our NF Endurance Team, a group of athletes that run, bike, swim, and compete in events across the country and abroad. The Endurance Team is comprised of a broad spectrum of athletes, from those who are running in a 5K for the first time to experienced IRONMAN competitors.

RAAM
Four women participated in the Race Across America (RAAM) event on behalf of the Children’s Tumor Foundation. Team members included CTF board member Lesley Oslica, Julie Hathcock, Hannah Turnbough, and NF Endurance staff member Angela Earle. These athletes rode constantly for 8 days and 18 hours, covering over 3,000 miles across 12 states.

“There is one goal that has not been met...and that’s to end NF. We will keep fighting, riding, running, walking, and fundraising.”
— Lesley Oslica, CTF Board Member and RAAM participant
Advocacy

Dedicated and passionate CTF volunteers advocate relentlessly for continual federal funding of NF research. We are pleased that $15 million in dedicated NF research funding was secured in the Fiscal Year 2015 congressional funding cycle. While these federal grants do not directly benefit the Foundation, the recipients of the grants are doing research that is of great value to everyone in the NF community.

The CTF government affairs team, comprised of CTF staff members, committee members, and CTF volunteers, at the guidance of outside counsel Squire Patton Boggs, continued to expand the breadth of its advocacy efforts in the second half of 2015, including active engagement with the Defense Health Research Consortium, which is now comprised of over 50 organizations dedicated to the preservation of annual funding levels for the Congressional Directed Medical Research Program (“CDMRP”) within the Department of Defense.

2015 also saw an unprecedented level of collaboration and strategic alignment with other organizations that support NF research funding, including the Littlest Tumor Foundation, Advocure NF2, Texas NF, Neurofibromatosis Network, NF Team Foundation, NF Midwest, and NF Inc. These collaborations culminated in a highly successful and well-attended Congressional briefing in December 2015 that served to educate key staff on the CDMRP’s NF research portfolio, including a highly effective presentation by CTF President Annette Bakker on NF research milestones.

“There is something very powerful in knowing that you have a voice with important issues and that you can be heard. For me, NF Advocacy has become not only my right, but my responsibility as a mother and a volunteer leader with the Children’s Tumor Foundation.”

— Connie Sorman, CTF Board Member, Volunteer Leadership Committee Chair, and NF Mom
Jeffrey Owen Hanson
Jeffrey Owen Hanson, world-renowned artist, was the 2015 Children’s Tumor Foundation Ambassador. Jeff is a 22-year-old philanthropic artist who is visually impaired due to an optic nerve glioma related to NF1. Though legally blind, the Kansas native has painted and donated more than $2 million in acrylic canvases to more than 150 charitable causes since 2006.

Jeff Hanson is also the 2015 winner of The NASCAR Foundation’s Betty Jane France Humanitarian Award, presented by Nationwide Insurance. The award embodies The NASCAR Foundation’s Founder Betty Jane France’s unwavering commitment to philanthropic causes, and recognizes those whose generosity and compassion have positively impacted the lives of children in their community.

Jeff and the Children’s Tumor Foundation received the most online votes out of four finalists who competed in a nationwide contest that lasted for nearly two months. In honor of Jeff’s win, the Children’s Tumor Foundation received a $100,000 donation from The NASCAR Foundation.

“I’m honored that my art and philanthropic efforts continue to fund neurofibromatosis research.”
— Jeffrey Owen Hanson, 2015 Children’s Tumor Foundation Ambassador
“Only 3% of the charities we rate have received at least 6 consecutive 4-star evaluations, indicating that the Children’s Tumor Foundation outperforms most other charities in America.”

— John P. Dugan, Charity Navigator Founder and Chairman of the Board

2015 was the sixth year in a row that the Children’s Tumor Foundation was honored with a 4-star rating from Charity Navigator, America’s largest independent evaluator of philanthropies. The Foundation is also accredited by the Better Business Bureau.
## Financial Summary

### Operating Support and Revenue

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions – individuals</td>
<td>$4,476,610</td>
<td>$8,394,155</td>
<td>$4,859,656</td>
</tr>
<tr>
<td>Contributions – corporations and foundations</td>
<td>$3,499,807</td>
<td>$2,034,159</td>
<td>$1,187,633</td>
</tr>
<tr>
<td>Bequests</td>
<td>$508</td>
<td>$108,398</td>
<td>$571,447</td>
</tr>
<tr>
<td>Contributed goods</td>
<td>$ 772,851</td>
<td>$412,821</td>
<td>$205,922</td>
</tr>
<tr>
<td>Other income</td>
<td>$ 56,252</td>
<td>$42,610</td>
<td>$229,554</td>
</tr>
<tr>
<td><strong>CONTRIBUTIONS AND OTHER INCOME</strong></td>
<td><strong>$8,806,028</strong></td>
<td><strong>$10,992,143</strong></td>
<td><strong>$7,054,212</strong></td>
</tr>
<tr>
<td>Special event revenue</td>
<td>$ 6,600,698</td>
<td>$5,121,565</td>
<td>$5,812,397</td>
</tr>
<tr>
<td>Less: direct benefits to donors</td>
<td>(405,301)</td>
<td>(385,917)</td>
<td>(325,326)</td>
</tr>
<tr>
<td>Special event revenue, net</td>
<td>$ 6,235,397</td>
<td>$4,735,648</td>
<td>$5,487,071</td>
</tr>
<tr>
<td><strong>TOTAL OPERATING &amp; SUPPORT REVENUE</strong></td>
<td><strong>$15,041,425</strong></td>
<td><strong>$15,727,791</strong></td>
<td><strong>$12,541,283</strong></td>
</tr>
</tbody>
</table>

### Operating Expenses

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research and medical</td>
<td>$7,935,871</td>
<td>$8,168,115</td>
<td>$6,357,258</td>
</tr>
<tr>
<td>Public education and patient support</td>
<td>$4,417,617</td>
<td>$3,954,550</td>
<td>$3,489,791</td>
</tr>
<tr>
<td><strong>TOTAL PROGRAM SERVICES</strong></td>
<td><strong>$12,353,488</strong></td>
<td><strong>$12,122,665</strong></td>
<td><strong>$9,847,049</strong></td>
</tr>
<tr>
<td>SUPPORT SERVICES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>$978,477</td>
<td>$852,967</td>
<td>$739,138</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$1,692,756</td>
<td>$1,553,773</td>
<td>$1,436,451</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORT SERVICES</strong></td>
<td><strong>$2,671,233</strong></td>
<td><strong>$2,406,740</strong></td>
<td><strong>$2,175,589</strong></td>
</tr>
<tr>
<td><strong>TOTAL OPERATING EXPENSES</strong></td>
<td><strong>$15,024,721</strong></td>
<td><strong>$14,529,405</strong></td>
<td><strong>$12,022,638</strong></td>
</tr>
</tbody>
</table>

### Change in Net Assets from Operations

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other changes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NON-OPERATING REVENUE</strong></td>
<td><strong>$73,229</strong></td>
<td><strong>$327,816</strong></td>
<td><strong>$646,463</strong></td>
</tr>
<tr>
<td><strong>Change in Net Assets</strong></td>
<td><strong>$89,933</strong></td>
<td><strong>$1,526,203</strong></td>
<td><strong>$1,165,108</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Assets, beginning of year</td>
<td>$10,348,522</td>
<td>$8,822,320</td>
<td>$7,657,212</td>
</tr>
<tr>
<td>Net Assets, end of year</td>
<td>$10,438,455</td>
<td>$10,348,522</td>
<td>$8,822,320</td>
</tr>
</tbody>
</table>

---

**ANNUAL REPORT 2015 | 19**
The Children’s Tumor Foundation depends on the continued support of many individuals, corporations, foundations, and communities that have joined in the fight against NF. To all those who have helped to advance the Foundation’s mission in the past, and especially to those who did so in 2015, we express our heartfelt gratitude.
The Children’s Tumor Foundation depends on the continued support of many individuals, corporations, foundations, and communities that have joined in the fight against NF. To all those who have helped to advance the Foundation’s mission in the past, and especially to those who did so in 2015, we express our heartfelt gratitude.

DONOR SPOTLIGHT: Moffett Family

Jim Bob & Laurée Moffett pledged in 2014 to match dollar for dollar contributions up to $2.5 million toward Synodos for NF1. Longtime supporters of the Children’s Tumor Foundation, the Moffetts’ involvement has extended to the NF Forum, the NF Conference, Racing4Research, the New York and Detroit Galas, and many other Foundation events. This incredible family is “all in” to help in the fight to find treatments and a cure for NF. The Moffetts believe that it is only through active giving and dedicated participation that, together, we can end NF.

With the help of the Moffetts and the many individuals who contributed to this matching gift fund, the $2.5 million match was met. Thank you Jim Bob and Laurée for making Synodos for NF1 a reality!
<table>
<thead>
<tr>
<th>Name</th>
<th>Company/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernie &amp; Mary Beth Buescher</td>
<td>Buffalo Wild Wings</td>
</tr>
<tr>
<td>Kathryn Bunn</td>
<td>Linda Burdick</td>
</tr>
<tr>
<td>The Burnham Foundation</td>
<td>Richard Burstein</td>
</tr>
<tr>
<td>Amy Butler</td>
<td>Cabela’s</td>
</tr>
<tr>
<td>Cabela’s</td>
<td>Eric Cagle</td>
</tr>
<tr>
<td>Chris Cahill</td>
<td>Charles Cain</td>
</tr>
<tr>
<td>Charles Cain</td>
<td>Jessica Caizza</td>
</tr>
<tr>
<td>Bobbie Noud Caleres</td>
<td>Calfee, Halter &amp; Griswold LLP</td>
</tr>
<tr>
<td>Calfee, Halter &amp; Griswold LLP</td>
<td>The Callaghan Family</td>
</tr>
<tr>
<td>Aidan &amp; Lyris Campbell</td>
<td>Rochelle Campbell</td>
</tr>
<tr>
<td>The Cancer Institute at NYU</td>
<td>Langone Medical Center</td>
</tr>
<tr>
<td>Michelle Cast</td>
<td>Larry Coffler</td>
</tr>
<tr>
<td>CB&amp;I Inc.</td>
<td>Daryl &amp; Sheila Cohoon</td>
</tr>
<tr>
<td>Central Florida Investments, Inc.</td>
<td>Colbeck Capital Management, LLC</td>
</tr>
<tr>
<td>Century 21 Beal</td>
<td>Todd &amp; Allison Cole</td>
</tr>
<tr>
<td>Joseph Cerbone</td>
<td>David Collier</td>
</tr>
<tr>
<td>Shane &amp; Sarah Cerone</td>
<td>Jonathan Collier</td>
</tr>
<tr>
<td>Cetcon, Inc.</td>
<td>Eric &amp; Mia Colodne</td>
</tr>
<tr>
<td>Henry Chace</td>
<td>Brigham G. Colton</td>
</tr>
<tr>
<td>Champlain Investment Partners, LLC</td>
<td>Richard &amp; Didi Colton</td>
</tr>
<tr>
<td>Jason &amp; Karen Chandler</td>
<td>Community Health Charities of California</td>
</tr>
<tr>
<td>The Charina Foundation, Inc.</td>
<td>Community Health Charities of NY</td>
</tr>
<tr>
<td>Chris &amp; Kristen Chase</td>
<td>Cone Health</td>
</tr>
<tr>
<td>ChemTreat, Inc.</td>
<td>Continuum Services, LLC</td>
</tr>
<tr>
<td>Daryl &amp; Sherry Chene</td>
<td>Roxanne Cook</td>
</tr>
<tr>
<td>Mark &amp; Sharon Chertok</td>
<td>Elische Cappuccio</td>
</tr>
<tr>
<td>Chick-fil-A</td>
<td>Copy Connection</td>
</tr>
<tr>
<td>Thomas Chiles</td>
<td>Crowley Animal Clinic, Inc.</td>
</tr>
<tr>
<td></td>
<td>William Cudney</td>
</tr>
<tr>
<td></td>
<td>Dustin &amp; Rhianna Curotto</td>
</tr>
<tr>
<td></td>
<td>Current Solutions, Inc.</td>
</tr>
<tr>
<td></td>
<td>Customlink, LLC</td>
</tr>
<tr>
<td></td>
<td>Stephen Cyper</td>
</tr>
<tr>
<td></td>
<td>Peter Damiris</td>
</tr>
<tr>
<td></td>
<td>Fred Damianos</td>
</tr>
<tr>
<td></td>
<td>Lisa Damman</td>
</tr>
<tr>
<td></td>
<td>Dan &amp; Lisa Dancsok</td>
</tr>
<tr>
<td></td>
<td>Jeffrey &amp; Wendy Dankey</td>
</tr>
<tr>
<td></td>
<td>Tim &amp; Debra Dansby</td>
</tr>
<tr>
<td></td>
<td>Patrick Darcy</td>
</tr>
<tr>
<td></td>
<td>David Daugherty</td>
</tr>
<tr>
<td></td>
<td>Nathan Daugherty</td>
</tr>
<tr>
<td></td>
<td>The David Foundation, Inc.</td>
</tr>
<tr>
<td></td>
<td>Ethan &amp; Gretchen Davidson</td>
</tr>
<tr>
<td></td>
<td>Rhonda &amp; Thomas Davis</td>
</tr>
<tr>
<td></td>
<td>Scott DeBates</td>
</tr>
<tr>
<td></td>
<td>Robert &amp; Annabella DiPilla</td>
</tr>
<tr>
<td></td>
<td>Lee &amp; Jenny Dodds</td>
</tr>
<tr>
<td></td>
<td>Dolan &amp; Kalaskey LTD</td>
</tr>
<tr>
<td></td>
<td>Arthur &amp; Alice Domby</td>
</tr>
<tr>
<td></td>
<td>Donatic</td>
</tr>
<tr>
<td></td>
<td>R. Bruce &amp; Madelyn Donoff</td>
</tr>
<tr>
<td></td>
<td>Greg Donovan</td>
</tr>
<tr>
<td></td>
<td>Brian Dooley</td>
</tr>
<tr>
<td></td>
<td>Timothy &amp; Sheila Drevarinno</td>
</tr>
<tr>
<td></td>
<td>David Dries</td>
</tr>
<tr>
<td></td>
<td>Michael D. Dubay</td>
</tr>
<tr>
<td></td>
<td>Kelly Dukla</td>
</tr>
<tr>
<td></td>
<td>Alexander Dunn</td>
</tr>
<tr>
<td></td>
<td>Nick Dunn</td>
</tr>
<tr>
<td></td>
<td>Dykema Gossett, PLLC</td>
</tr>
<tr>
<td></td>
<td>EAM Land Services, Inc.</td>
</tr>
<tr>
<td></td>
<td>Robin Early</td>
</tr>
<tr>
<td></td>
<td>David &amp; Gayle Ebel</td>
</tr>
<tr>
<td></td>
<td>Mark Ebel &amp; Catherine Laskey</td>
</tr>
<tr>
<td></td>
<td>Michael Capasso</td>
</tr>
<tr>
<td></td>
<td>Ron Capp</td>
</tr>
<tr>
<td></td>
<td>Tim Caress</td>
</tr>
<tr>
<td></td>
<td>Caribbean K-8 Center</td>
</tr>
<tr>
<td></td>
<td>Caribou Cabins</td>
</tr>
<tr>
<td></td>
<td>Carlock, Copeland &amp; Stair, LLC</td>
</tr>
<tr>
<td></td>
<td>Candy Carlott</td>
</tr>
<tr>
<td></td>
<td>Gillian Carpenter</td>
</tr>
<tr>
<td></td>
<td>Daryl Carter</td>
</tr>
<tr>
<td></td>
<td>Samuel &amp; Heather Carter</td>
</tr>
<tr>
<td></td>
<td>Stephen &amp; Karen Carter</td>
</tr>
<tr>
<td></td>
<td>Daniel &amp; Diane Caruso</td>
</tr>
<tr>
<td></td>
<td>CarVal Investors</td>
</tr>
<tr>
<td></td>
<td>Sean Casey</td>
</tr>
<tr>
<td></td>
<td>Louis N. Cassett Foundation</td>
</tr>
<tr>
<td>Samantha Chin</td>
<td>Michelle Cast</td>
</tr>
<tr>
<td>Chipotle Mexican Grill</td>
<td>Larry Coffler</td>
</tr>
<tr>
<td>CHMWarrick, LLC</td>
<td>Daryl &amp; Sheila Cohoon</td>
</tr>
<tr>
<td>Barbara Choudhury</td>
<td>Coilbeck Capital Management, LLC</td>
</tr>
<tr>
<td>Christopher’s Seafood and Prime Steak House</td>
<td>Todd &amp; Allison Cole</td>
</tr>
<tr>
<td>Tracy Church</td>
<td>David Collier</td>
</tr>
<tr>
<td>Cirque Du Soleil Holding</td>
<td>Jonathan Collier</td>
</tr>
<tr>
<td>USA INC.</td>
<td>Eric &amp; Mia Colodne</td>
</tr>
<tr>
<td>Gregg Clark</td>
<td>Brigham G. Colton</td>
</tr>
<tr>
<td>Kip &amp; Allison Clarke</td>
<td>Richard &amp; Didi Colton</td>
</tr>
<tr>
<td>Robert Clarke</td>
<td>Community Health Charities of California</td>
</tr>
<tr>
<td>Clarke Glassboard</td>
<td>Community Health Charities of NY</td>
</tr>
<tr>
<td>Raymond Cloutier</td>
<td>Cone Health</td>
</tr>
<tr>
<td>Catherine Coakley</td>
<td>Continuum Services, LLC</td>
</tr>
<tr>
<td></td>
<td>Roxanne Cook</td>
</tr>
<tr>
<td></td>
<td>Elische Cappuccio</td>
</tr>
<tr>
<td></td>
<td>Copy Connection</td>
</tr>
<tr>
<td></td>
<td>Crowley Animal Clinic, Inc.</td>
</tr>
<tr>
<td></td>
<td>William Cudney</td>
</tr>
<tr>
<td></td>
<td>Dustin &amp; Rhianna Curotto</td>
</tr>
<tr>
<td></td>
<td>Current Solutions, Inc.</td>
</tr>
<tr>
<td></td>
<td>Customlink, LLC</td>
</tr>
<tr>
<td></td>
<td>Stephen Cyper</td>
</tr>
<tr>
<td></td>
<td>Peter Damiris</td>
</tr>
<tr>
<td></td>
<td>Fred Damianos</td>
</tr>
<tr>
<td></td>
<td>Lisa Damman</td>
</tr>
<tr>
<td></td>
<td>Dan &amp; Lisa Dancsok</td>
</tr>
<tr>
<td></td>
<td>Jeffrey &amp; Wendy Dankey</td>
</tr>
<tr>
<td></td>
<td>Tim &amp; Debra Dansby</td>
</tr>
<tr>
<td></td>
<td>Patrick Darcy</td>
</tr>
<tr>
<td></td>
<td>David Daugherty</td>
</tr>
<tr>
<td></td>
<td>Nathan Daugherty</td>
</tr>
<tr>
<td></td>
<td>The David Foundation, Inc.</td>
</tr>
<tr>
<td></td>
<td>Ethan &amp; Gretchen Davidson</td>
</tr>
<tr>
<td></td>
<td>Rhonda &amp; Thomas Davis</td>
</tr>
<tr>
<td></td>
<td>Scott DeBates</td>
</tr>
<tr>
<td></td>
<td>Robert &amp; Annabella DiPilla</td>
</tr>
<tr>
<td></td>
<td>Lee &amp; Jenny Dodds</td>
</tr>
<tr>
<td></td>
<td>Dolan &amp; Kalaskey LTD</td>
</tr>
<tr>
<td></td>
<td>Arthur &amp; Alice Domby</td>
</tr>
<tr>
<td></td>
<td>Donatic</td>
</tr>
<tr>
<td></td>
<td>R. Bruce &amp; Madelyn Donoff</td>
</tr>
<tr>
<td></td>
<td>Greg Donovan</td>
</tr>
<tr>
<td></td>
<td>Brian Dooley</td>
</tr>
<tr>
<td></td>
<td>Timothy &amp; Sheila Drevarinno</td>
</tr>
<tr>
<td></td>
<td>David Dries</td>
</tr>
<tr>
<td></td>
<td>Michael D. Dubay</td>
</tr>
<tr>
<td></td>
<td>Kelly Dukla</td>
</tr>
<tr>
<td></td>
<td>Alexander Dunn</td>
</tr>
<tr>
<td></td>
<td>Nick Dunn</td>
</tr>
<tr>
<td></td>
<td>Dykema Gossett, PLLC</td>
</tr>
<tr>
<td></td>
<td>EAM Land Services, Inc.</td>
</tr>
<tr>
<td></td>
<td>Robin Early</td>
</tr>
<tr>
<td></td>
<td>David &amp; Gayle Ebel</td>
</tr>
<tr>
<td></td>
<td>Mark Ebel &amp; Catherine Laskey</td>
</tr>
<tr>
<td></td>
<td>Michael Capasso</td>
</tr>
<tr>
<td></td>
<td>Ron Capp</td>
</tr>
<tr>
<td></td>
<td>Tim Caress</td>
</tr>
<tr>
<td></td>
<td>Caribbean K-8 Center</td>
</tr>
<tr>
<td></td>
<td>Caribou Cabins</td>
</tr>
<tr>
<td></td>
<td>Carlock, Copeland &amp; Stair, LLC</td>
</tr>
<tr>
<td></td>
<td>Candy Carlott</td>
</tr>
<tr>
<td></td>
<td>Gillian Carpenter</td>
</tr>
<tr>
<td></td>
<td>Daryl Carter</td>
</tr>
<tr>
<td></td>
<td>Samuel &amp; Heather Carter</td>
</tr>
<tr>
<td></td>
<td>Stephen &amp; Karen Carter</td>
</tr>
<tr>
<td></td>
<td>Daniel &amp; Diane Caruso</td>
</tr>
<tr>
<td></td>
<td>CarVal Investors</td>
</tr>
<tr>
<td></td>
<td>Sean Casey</td>
</tr>
<tr>
<td></td>
<td>Louis N. Cassett Foundation</td>
</tr>
<tr>
<td></td>
<td>Michael Capasso</td>
</tr>
<tr>
<td></td>
<td>Ron Capp</td>
</tr>
<tr>
<td></td>
<td>Tim Caress</td>
</tr>
<tr>
<td></td>
<td>Caribbean K-8 Center</td>
</tr>
<tr>
<td></td>
<td>Caribou Cabins</td>
</tr>
<tr>
<td></td>
<td>Carlock, Copeland &amp; Stair, LLC</td>
</tr>
<tr>
<td></td>
<td>Candy Carlott</td>
</tr>
<tr>
<td></td>
<td>Gillian Carpenter</td>
</tr>
<tr>
<td></td>
<td>Daryl Carter</td>
</tr>
<tr>
<td></td>
<td>Samuel &amp; Heather Carter</td>
</tr>
<tr>
<td></td>
<td>Stephen &amp; Karen Carter</td>
</tr>
<tr>
<td></td>
<td>Daniel &amp; Diane Caruso</td>
</tr>
<tr>
<td></td>
<td>CarVal Investors</td>
</tr>
<tr>
<td></td>
<td>Sean Casey</td>
</tr>
<tr>
<td></td>
<td>Louis N. Cassett Foundation</td>
</tr>
</tbody>
</table>
DONOR SPOTLIGHT: Cupid’s Undie Run

February 2015 marked the sixth consecutive Cupid’s Undie Run to benefit the Children’s Tumor Foundation. Cupid’s has grown in leaps and bounds since 2010, when participants raised $10,000, to 2015, when more than $3.2 million was raised for NF research. Everyone’s favorite Valentine’s Day-themed party has shown what an amazing group of generous do-gooders will do for an important cause. Always ready to express some “hilarity for charity” and never afraid of “freezin’ for a reason,” these cherubs take the NF fight to 35 cities across the United States as well as 3 cities in Australia. The Children’s Tumor Foundation is grateful for Cupid’s willingness to take such bold, creative steps to find a cure for NF.

James & Renee Harrell
William & Lenore Harris
Robert Harrison
John Hartzell
Christina Hatch
Head Hunters Salon & Day Spa
Thomas & Elizabeth Heffron
Sharon Hefflin
Jeff & Jill Hennig
Jacqueline Henry
Robert Hensley

G.W. Hensler & Associates, LTD
Susan Herbach
Heritage Vision Plans, Inc.
Linda & Ronny Herland
The Hermelin Family Support Foundation
Maurice & Jacqueline Herz
Derek Latika & Blair Hess
Marcus Hester
Herren & Susan
Hickingbotham
Barbara K. Hicks
Tod Highfield
Elaine Hill
Michael Hill
Harold Hilley
Jason S. & Meredith Hillman
Kenneth Hines
HMC Presents – Jingle Bells
for Cancer Cells
Stephan & Deborah Hodge
Jeff Hoen
Lisa Hofer
William Hoffman
Jon Holstrom
Paul Holton
Home Buyers Marketing, Inc.
The Home Depot
Tammy & Randy Homer
Earl Horshner
Peter & Dana Hopper
Hormel Foods Corporation
Brian Hoskins
Lindsay Hostetter
Theodore Houck
Kevin & Lisa Houle
Jane Howland
Ed & Betsy Huben
Richard & Marianne Huelsmann
Dan & Kim Huish
Steven Hummel
Jerry & Maureen Hunter
Huntington Bank
Michael & Donna Hussey
Mark & LaDeana Huylar
Bill Hyde
I.C.A.N. Foods, Inc.
I.U.O.E. Local 12
Iberdrola Renewables Holdings, Inc.
Image One Corporation
Imagine Paul Mitchell
Leila Imhof
Impact Golf Center
Insignia National Title Agency, LLC
International Motor Sports Association, LLC
International Union of Operating Engineers Local 12
Ironman World Triathlon Corporation
Becky & Lance Irvine
Jackson Thornton & Co., P.C.
David & Dana Jacob
Damaris Jacques
Richard & Amanda Jaffa
Jaffe, Rait, Heuer & Weiss
Nicole Jala
Nasser & Samia Jallad
Jennifer Jeandron
Jesse & Tyler Jenner
Douglas C. Jennings
Brian & Heidi Jensen
Hans & Barbara Jeppson
John Deere Construction & Forestry Company
Eric & Mary Beth Johnson
Van Johnson
Mark Johnson & Associates
Chris & Sarah Jones
Harry & Riki Jones
Kenneth R. Jordan
Jerry J. Jusek
JV Kelley Enterprise LLC
Michael Kaczmarek
Robert Kahn
Michelle Kann
Barry & Rochelle Kaplan
Barbara Ann Karmanos Cancer Institute
Richard & Leslie Kates
Aubrey & Roleen Katz
The Rachel & Drew Katz Foundation, Inc.
David & Heather Katzman
Steven & Elizabeth Katzman
George & Mariana Kaufman
Scott Kaufman
Andrew Kean
Susan Kean
Joe & Linda Keller
Barry & Lynda Keller
Community Fund II
Allen & Vickie Kelley
L. Michael & Karen Kelly
Harris & Eliza Kemper Fund
Kendra Scott Design, Inc.
Kenneth Jay Lane
Bridget KerMorris
Penn Ketchum
Melissa Kieran
Luci Kirk
Kiwanis Club of Midlothian
Annemarie Kleabir
Ronald & Stacy Klein
George Klett
Ron & Tamara Knapp
Ryan & Rene Knapp
Knights Of Columbus - Council No. 4567
Kohl’s Department Stores
George & Jutta Kohn
Laura A. Krietemeyer
Mark & Sherry Kronenfeld
Robert & Jeri Krueger
Kruger Jewelry Co., Inc. of Austin
Carol D. Kulluk
Liang Kung & Jane Chiang Lin
Murray & Lee Kushner
Marshall Kutz
Amy Kuzdowicz
Lawrence & Anita LaBarbera
Chris Labelle
Doug & Melissa Labelle Family Foundation
Dana Labes
Rocco Laginestra
Robert & Tonya Lambert
Melissa Landau
Mickey & Linda Landis
Landon Outreach Foundation
David Lang
Langan Engineering & Environmental Services, Inc.
Noel & Trish LaPorte
Steve LaPorte
Jason & Kimberly LaRose
Last Call Operating Co. I, Inc.
Cheryl Lau
Margaret Kohn
Leonard & Denise Komoroski
Mark & Carrie Korth
Michael & Linda Kowalk
Krabby Painters Inc.
Kramer Levin Naftalis & Frankel, LLP
Kramer Portraits
Douglas Lautner
Sarah Le Clerc
Lead Intelligence, Inc.
John & Edyth Ledbetter
Ronald & Debra Lederman
The Ed Lee & Jean Campe Foundation, Inc.
L. Lee & Carole Hodges
A playful time was had by more than 1,500 attendees at the third annual Detroit beNeFit, “A Playdate to End NF.” Hosted by esteemed CTF patrons Jennifer and Dan Gilbert, “The beNeFit” was held in November at the Cobo Center in Detroit, Michigan, bringing in a record $5.2 million for NF research. The numerous supporters who came out to play were invited to “wear your dress-up clothes” and enjoy a night of “drinks, dinner, and afterglow.” Presented amid giant toys and a cartoon cityscape, the evening’s entertainment included silent and live auctions. Among those in attendance were many business leaders and most of the 2016 NBA Championship Cleveland Cavaliers.

Dan and Jennifer are parents to NF Hero Nick Gilbert, and they created “The beNeFit” in 2013 as an inspirational annual extravaganza to raise funds and increase awareness of NF. The Gilberts’ hard work, dedication, and vision have translated into nearly $11 million raised in three years for the Children’s Tumor Foundation. Thank you, Dan and Jennifer for your unending support!
with Thanks

R. Wayne & Emily Ogozaly
Ohio Valley Porsche Club of America
Richard & Caroline Olgee
John & Cathy Olzewske
Joe Oltman
Barbara Oosterwyk
Organization for Autism Research
Michael Ortiz
Connie & Lesley Oslica
Our Lady of Grace Catholic School
John & Diane Owens
Lisa Oyen
George & Sandra Pace
Lloyd Pace
Lizbeth Pagan
Cherie Page
Pak’s Karate Academy of Mandarin
Jim Palmer
Ronald Palmese
Matthew Parker
Ralph & Lisa Pascucci
Ruth Pash
Patagonia, Inc.
Nicholas & Josephine Pedone
Roger & Kathy Penske
The PepsiCo Silicon Valley Community Foundation
Shannon Perez
Perfect Touch Painting
Anthony & Laura Perfetti
Leigh Perkins
Perkins Coie Trust Company
Bruce Israel & Lisa Pernick
Perrigo Company Foundation
Alison Peterson
Don Pfeifer
Pfizer Foundation
Erik & Robin Phelps
Melody Piazza
Starr Piner
Zach & Michelle Piner
Jeffrey & Emily Pitt
Pleasant Valley School District
John & Kristine Poirier
Police and Fire Federal Credit Union
Ralph & Ann Pollack
The Nancy C. Pollard Charitable Fund
Evan Ponz
Craig & Sarah Pope
Michael Popovic
Portofino Restaurant Inc.
Premier Creative Group
Prestige Care, Inc.
Paul & Angel Price
Principal Financial Group Foundation, Inc.
Andrew & Denelle Pritchard
Kevin & Kathryn Prokop
Property Markets Group, Inc.
Publicis LifeBrands Evolvr
Bill Pulte
Amanda Pylate
George Pyne
Quest Diagnostics
Howard Rachlin
Randall-Paulson Architects, Inc.
Eric Randolph
Brian & Pat Ratner
Noah & Kristy Ravenscroft
Kristin Rawl
Andrew & Heather Rayburn
Judith & Donald Rechler Foundation
Trent Redden
Mike & Sandie Redfern
Reed Smith, LLP
The Dale L. Reese Foundation
Michael & Gayle Regan
Regional Appraisal Association, Inc.
Daniel & Joan Reilly
Reliant Holdings, Inc.
Mary Renna
Stephen Repsher & Kathleen Wilcox
Republic Finance, LLC
Reynolds Family Foundation
RFI Construction Management, Inc.
Melvin & Patricia Rice
Robyn Lowery Richardson
Richmond University Medical Center
Anne Riesbeck
Ritchie Bros. Auctioneers, Inc.
Robert Rivenburgh
Charles & Donna Robb
Alan & Jerye Ann Robbins
Norman & Bettina Roberts Foundation, Inc.
Jared Roberts
Jeff Robertson
James & Barbara Robinson
Jaylyn Robison
Rock Box
Rock-Pond Solutions
Mitchell & Elizabeth Rodbell
Luis Rodriguez
Florence Roffman
Phil Rogacki
Kelli Rogan
Robert & Pamela Rogan
Barry & Jody Rogow
Tom Roland & Betsy Pfeffer
Gerard & Alice Marie Rorke
Kathryn Rose
Eleanore Rosenberg
Laurence & Lori Rosenberg
Roslyn High School
Gloria F. Ross Foundation, Inc.
Kurt Ross
Toni Ross
George Rosser
Matthew Rossetti
Robert Rostron
Rota Portrait Design

Michael & Melanie Rothenberg
Ronald & Carol Rothrock
Jean Rothschild
Charles & Diana Rothstein
Julie & Adam Rothstein
Ronald & Ursula Rottloff
The Patrick Michael Rubin Scholarship Fund, Inc.
Nicholas Rudd
Kenneth C. Rudd, Esq.
Kurt & Lucia Rueckel
Mary Ruggeri
David & Cindy Rulon
Edward Russnow
Dan & Julie Rutter
Marcia Ryan
SaalGood
Todd & Karen Sachse
Sachse Construction
Sacramento Adventist Academy
Safety Insurance
Saks Fifth Avenue
The Salesforce.com Foundation
Susan Salketer
Smita Sampath
Ross & Maryann Sanders
Sanford Medical Center Fargo
William & Christina Sargent
Arnab Sarkar
SBC Hospitality Ministry
Dick & Carolan Scanlan
Andrew & Amy Schafer
Ethan Schapira & Dacia Cocaru
Richard & Linda Schaps
Robert & Bluma Schechter
Michael Scherl
Scott Schultz
DONOR SPOTLIGHT: Flashes of Hope

Flashes of Hope
Quicken Loans Arena transformed into Motown last November, as the Cleveland Cavaliers and Flashes of Hope welcomed 1,000 guests for the 2015 Big Shots and Little Stars fundraiser. The annual event benefits Flashes of Hope and the Children’s Tumor Foundation.

Allison Clarke, founder of Flashes of Hope, and Dan Gilbert, CTF Board Member and majority owner of the Cleveland Cavaliers basketball team, kicked off the evening. The highlight of the night was the runway show. The Cavaliers roster was joined by other “Big Shots” from the Cleveland business community, who escorted their “Little Stars” – pediatric cancer survivors – down the runway.

Flashes of Hope is a nonprofit organization that raises funds to accelerate a cure for children’s cancers while honoring the unique life and memories of every child fighting cancer.

Thanks to the Big Shots and Little Stars event, Flashes of Hope made a donation of $600,000 to the Children’s Tumor Foundation, which will go toward critical research into malignant peripheral nerve sheath tumors.

The Children’s Tumor Foundation extends our utmost thanks to Kip and Allison Clarke, Dan Gilbert, and the Cleveland Cavaliers, to all the Big Shots and Little Stars, and to Flashes of Hope for their continued support in funding NF research.
“NF may currently have no cure, but that doesn’t mean there is no hope. I fully believe that I can still achieve my life goals and dreams, albeit on a different timeline than what I had originally envisioned. I may have NF, but NF doesn’t have me.”

— Nora Wade, who lives with NF
Board of Directors
Linda Halliday Martin, Chair
Rachel B. Tiven, Vice Chair
Randall Stanicky, Treasurer
Tracy Galloway, Secretary
Bruce R. Korf, MD, PhD, Chair, Medical Advisory Committee
Stuart Match Suna, Chair Emeritus
Connie Sorman, Volunteer Leadership Council Chair

Daniel Altman
Laura Ganio Bona
Robert Brainin
William Brooks
Suzanne Earle
Daniel Gilbert
John Golfinos, MD
Brendan Hanrahan, PhD
Matthew Hay
Chad Leathers
John McCarthy
Steven L. McKenzie
Lesley Oslica
Laura Perfetti
Kenneth Rudd
Karl Thomson
Dave Viskochil, MD, PhD
Nate Walker
Peggy Wallace, PhD

Honorary Directors
Richard A. Horvitz
Michie Stovall O’Day
Alan Robbins, MD
Carolyn E. Setlow

Ed Stern
Pro Bono Counsel
Allan Rubenstein, MD, Director of Medical Affairs Emeritus

Medical Advisory Committee
Bruce Korf, MD, PhD, Chair
Jaishri Blakeley, MD, PhD
Karen Cichowski, PhD
Suzanne Earle
Tracy Galloway
Peter Linsley, PhD
Michael Morin, PhD
Marco Nievo, PhD
Roger Packer, PhD
Scott Plotkin, MD, PhD
Stuart Match Suna
Ed Stern
Dave Viskochil, MD, PhD
Peggy Wallace, PhD

Foundation Staff
Annette Bakker, PhD, President and Chief Scientific Officer
Reid Horovitz, Chief Operating Officer and Chief Financial Officer

Research and Medical Programs
Salvatore La Rosa, PhD, Vice President, Research and Development
Maria Carela, Grant Manager
Vidya Dhote, PhD, Basic Science Manager
Kate Kelts, Patient Support Coordinator
Pamela Knight, Clinical Program Director
Hyerim Lee, PhD, Transitional Science Project Director
Patrice Pancza, Program Director, Research
Heather Radtke, NF Clinic and Symposium Coordinator
Sarah Rosenberg, Executive Assistant

Development and Community Relations
Michael Divers, Vice President, Development
Melissa Sosa-Longo, Vice President, Major Gifts
Jill Beck, Program Director, Racing4Research
Jessica Beckerman, NF Walk Development Manager
Allison Cote, Regional Development Manager
Emily Crabtree, Program Director, NF Endurance
Rebecca De Orelmas, National Manager, Special Events
Paul Dranginis, Director, Major Gifts
Angela Dumaday, NF Endurance Manager
Angela Earle, NF Endurance Manager
Adam Gracia, Regional Development Manager
Lolita Jerido, Regional Development Manager
Kelly Mills, Regional Development Manager
Julie Pantoliano, Regional Development Manager
Kristine Poirier, Director, Regional Development and NF Walk
Kim Robinson, Regional Development Coordinator
Traceann Rose, Director, Community Building and Patient Engagement
Mary Vetting, Stewardship Manager
Lauren Walsh, NF Endurance Manager

Finance and Administration
Catherine Blessing, Human Resources Director
Sarah Bourne, Director of Finance
Monique Boucher, Gift Processing Manager
Albert Diaz, Director of IT and Salesforce Administration
Margaret Flaccamio, Fulfillment Coordinator
Keena Hutchinson, Gift Processing Coordinator
Latisha Maxwell, Gift Processing Coordinator
Danielle Meyer, Technical Support, National Programs
Carey Milligan, Accountant
Rosa Amelia Perez, Project Administrator

Marketing and Communications
Simon Vukelj, Vice President, Marketing and Communications
Alissa Marks, Marketing Manager
Susanne Preinfalk, Design Director
Rebecca Harris, Public Relations Manager
Vanessa Younger, Communications Senior Manager

Staff list as of 9/30/2016